451 related articles for article (PubMed ID: 27462088)
21. Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006-2015.
Maloney-Hall B; Wallingford SC; Konefal S; Young MM
Health Promot Chronic Dis Prev Can; 2020 Jun; 40(5-6):176-183. PubMed ID: 32529977
[TBL] [Abstract][Full Text] [Related]
22. Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome.
Auther AM; McLaughlin D; Carrión RE; Nagachandran P; Correll CU; Cornblatt BA
Psychol Med; 2012 Dec; 42(12):2485-97. PubMed ID: 22716931
[TBL] [Abstract][Full Text] [Related]
23. Synthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: A retrospective electronic case register study.
Hobbs M; Patel R; Morrison PD; Kalk N; Stone JM
J Psychopharmacol; 2020 Jun; 34(6):648-653. PubMed ID: 32108548
[TBL] [Abstract][Full Text] [Related]
24. Psychiatric effects of cannabis.
Johns A
Br J Psychiatry; 2001 Feb; 178():116-22. PubMed ID: 11157424
[TBL] [Abstract][Full Text] [Related]
25. Cannabis use and psychiatric and cogitive disorders: the chicken or the egg?
Di Forti M; Morrison PD; Butt A; Murray RM
Curr Opin Psychiatry; 2007 May; 20(3):228-34. PubMed ID: 17415074
[TBL] [Abstract][Full Text] [Related]
26. Evidence for the Risks and Consequences of Adolescent Cannabis Exposure.
Levine A; Clemenza K; Rynn M; Lieberman J
J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):214-225. PubMed ID: 28219487
[TBL] [Abstract][Full Text] [Related]
27. Hospital Stay in Synthetic Cannabinoid Users With Bipolar Disorder, Schizophrenia, or Other Psychotic Disorders Compared With Cannabis Users.
Deng H; Desai PV; Mohite S; Okusaga OO; Zhang XY; Nielsen DA; Kosten TR
J Stud Alcohol Drugs; 2019 Mar; 80(2):230-235. PubMed ID: 31014468
[TBL] [Abstract][Full Text] [Related]
28. Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016.
Hjorthøj C; Larsen MO; Starzer MSK; Nordentoft M
Psychol Med; 2021 Mar; 51(4):617-622. PubMed ID: 31839011
[TBL] [Abstract][Full Text] [Related]
29. U-shaped curve of psychosis according to cannabis use: New evidence from a snowball sample.
Brañas A; Barrigón ML; Garrido-Torres N; Perona-Garcelán S; Rodriguez-Testal JF; Lahera G; Ruiz-Veguilla M
J Psychopharmacol; 2016 Dec; 30(12):1331-1338. PubMed ID: 27539930
[TBL] [Abstract][Full Text] [Related]
30. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis.
Mensen VT; Vreeker A; Nordgren J; Atkinson A; de la Torre R; Farré M; Ramaekers JG; Brunt TM
Psychopharmacology (Berl); 2019 Sep; 236(9):2677-2685. PubMed ID: 30968175
[TBL] [Abstract][Full Text] [Related]
31. Substance-induced psychotic disorders: 13-year data from a de-addiction centre and their clinical implications.
Aggarwal M; Banerjee A; Singh SM; Mattoo SK; Basu D
Asian J Psychiatr; 2012 Sep; 5(3):220-4. PubMed ID: 22981049
[TBL] [Abstract][Full Text] [Related]
32. Pathways to psychosis in cannabis abuse.
Shrivastava A; Johnston M; Terpstra K; Bureau Y
Clin Schizophr Relat Psychoses; 2015 Apr; 9(1):30-5. PubMed ID: 23491968
[TBL] [Abstract][Full Text] [Related]
33. A survey of synthetic cannabinoid consumption by current cannabis users.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Subst Abus; 2014; 35(2):184-9. PubMed ID: 24821356
[TBL] [Abstract][Full Text] [Related]
34. Cannabis use in a large sample of acute psychiatric admissions.
Mathers DC; Ghodse AH; Caan AW; Scott SA
Br J Addict; 1991 Jun; 86(6):779-84. PubMed ID: 1878628
[TBL] [Abstract][Full Text] [Related]
35. Differences in associations between cannabis and stimulant disorders in first admission psychosis.
Sara G; Burgess P; Malhi GS; Whiteford H; Hall W
Schizophr Res; 2013 Jul; 147(2-3):216-22. PubMed ID: 23684162
[TBL] [Abstract][Full Text] [Related]
36. Psychosis and cannabis abuse in The Gambia. A case-control study.
Rolfe M; Tang CM; Sabally S; Todd JE; Sam EB; Hatib N'Jie AB
Br J Psychiatry; 1993 Dec; 163():798-801. PubMed ID: 8306122
[TBL] [Abstract][Full Text] [Related]
37. [Cannabis and psychosis--a review].
Schaub M; Rössler W; Stohler R
Praxis (Bern 1994); 2004 Jun; 93(23):997-1002. PubMed ID: 15233568
[TBL] [Abstract][Full Text] [Related]
38. Synthetic cannabinoids: the dangers of spicing it up.
Salani DA; Zdanowicz MM
J Psychosoc Nurs Ment Health Serv; 2015 May; 53(5):36-43. PubMed ID: 25974923
[TBL] [Abstract][Full Text] [Related]
39. Long-term risk factors for substance-induced and primary psychosis after release from prison. A longitudinal study of substance users.
Rognli EB; Berge J; Håkansson A; Bramness JG
Schizophr Res; 2015 Oct; 168(1-2):185-90. PubMed ID: 26359848
[TBL] [Abstract][Full Text] [Related]
40. [Cannabis use and the risk of psychotic disorders. An update].
Kuepper R; van Winkel R; Henquet C
Tijdschr Psychiatr; 2013; 55(11):867-72. PubMed ID: 24242146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
